Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096779 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT06096779 is a Phase 2 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Genentech. The registered enrollment target is 30 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06096779, a Phase 2 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of Southern California-Keck School of Medicine -1975 Zonal Ave - Los Angeles
- University of Southern California - Newport Beach
- University of California Irvine Medical Center - Orange
- California Liver Research Institute - Pasadena
- University of California Davis Medical Center - Sacramento
- Stanford Health Care - Stanford
- Harbor UCLA Medical Center - Torrance
- Cedars Sinai Comprehensive Transplant Center - West Hollywood
Illinois
- Northwestern University - Chicago
- University of Illinois Health Outpatient Care Center - Chicago
- The Duchossois Center for Advanced Medicine - Chicago
Louisiana
- LSU Health Baton Rouge - Baton Rouge
- Our Lady of the Lake Physician Group - Baton Rouge
Arizona
- University of Arizona Cancer Center - Tucson
Colorado
- Rocky Mountain Cancer Centers (Williams) - USOR - Denver
Connecticut
- Hartford Healthcare Cancer Institute at Hartford Hospital - Hartford
District of Columbia
- Washington DC VA Medical Center - Washington D.C.
Florida
- Orlando Health Inc. - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06096779
The ClinicalTrials.gov registry entry for NCT06096779 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT06096779 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06096779 about?
NCT06096779 is a clinical study titled "A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis". The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
What is the current status of trial NCT06096779?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-07-15. Estimated completion is 2027-12-30.
What conditions does trial NCT06096779 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06096779?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT06096779?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06096779 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.